Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Nurix Therapeutics shares are up in premarket trading after announcing a collaboration with Roche to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader. The deal supports Nurix's pipeline and adds external validation for its drug-discovery platform. The move is positive for the stock, though the article provides no deal economics or regulatory milestone.

Analysis

Nurix Therapeutics shares are up in premarket trading after announcing a collaboration with Roche to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader. The deal supports Nurix's pipeline and adds external validation for its drug-discovery platform. The move is positive for the stock, though the article provides no deal economics or regulatory milestone.